Picterus AS

Picterus AS is a medical technology company founded in 2015 in Trondheim, Norway. It develops scalable, research-based solutions to improve newborn care, beginning with neonatal jaundice — a condition that affects the majority of newborns worldwide. The company's flagship offering, Picterus Jaundice Pro, is a fully certified medical app that combines a smartphone application with a color calibration card to perform fast, accurate, and non-invasive bilirubin screening. The solution is designed for use by healthcare professionals in clinical settings as well as by parents and midwives for follow-up care at home. The company states that its app is CE-certified as a class IIa medical device and that its technology is protected by a portfolio of patents. Picterus reports clinical validation in more than 5,000 newborns across 15+ countries, over 9,000 verified scans, and use by more than 500 healthcare professionals. It also claims one of the world's largest bilirubin databases. The screening solution is designed to work on all skin tones and has been used to screen over 10,000 newborns according to the company's homepage. Picterus positions its product for both high-resource and low-resource settings, emphasizing accessibility and early detection. The company's care model spans screening before hospital discharge, home visits by midwives or trained healthcare workers, and independent parent use with remote follow-up supported by healthcare providers. This flexible approach aims to improve continuity of care and reduce hospital readmissions. In 2025, Picterus established Picterus Newborn Health, a nonprofit organization focused on advancing global equity in newborn care through jaundice awareness, education, and access to screening in low-resource settings. The company continues to develop its next-generation model, with a stated goal of broader inclusivity and best performance to date.

Picterus AS was founded in 2015 in Trondheim, Norway, as a medical technology company with a global reach. According to the company's own timeline, the period 2012–2016 covered concept and feasibility research, followed by clinical validation and patented technology development in 2017–2020. In 2021–2022, Picterus achieved its first CE-marked medical device. The years 2023–2024 saw expanded clinical use and usability improvements. From 2025 onward, the company is working on a next-generation model with broader inclusivity and what it describes as its best performance to date. The company's flagship product, Picterus Jaundice Pro, is a smartphone-based screening solution for neonatal jaundice that uses an app and a color calibration card. It is described as a fully certified medical app, CE-certified as a class IIa medical device, and is designed to offer fast, accurate, and non-invasive bilirubin screening. The solution is intended for use in clinical settings as well as for follow-up care at home. Picterus reports that its technology has been clinically validated in more than 5,000 newborns across 15+ countries, with over 9,000 verified scans and more than 500 healthcare professionals using the product. The company also states it has one of the world's largest bilirubin databases. Its homepage notes that over 10,000 newborns have been screened and that the solution works on all skin tones. In 2025, Picterus established Picterus Newborn Health, a nonprofit organization committed to advancing global equity in newborn care. This organization focuses on jaundice awareness, education, and access to care, working with local communities, partners, and governments to deliver screening solutions to newborns in low-resource settings. The company's mission is to revolutionize neonatal jaundice care by offering a universally accessible and accurate screening solution, ensuring a healthy start for every child, anywhere and anytime.

• 2025

  Established Picterus Newborn Health nonprofit; next-generation model development begins.

• 2023

  Expanded clinical use and usability improvements (2023–2024).

• 2021

  First CE-marked medical device (2021–2022).

• 2017

  Clinical validation and patented technology development (2017–2020).

• 2015

  Founded in Trondheim, Norway.

• 2012

  Concept and feasibility research begins (2012–2016).

Accessible, accurate, non-invasive neonatal jaundice screening for clinical and home settings worldwide.

• Picterus Jaundice Pro

  Smartphone-based neonatal jaundice screening app using a color calibration card; CE-certified class IIa medical device.

• Picterus Calibration Card

  Color calibration card used with the Picterus Jaundice Pro app for accurate bilirubin screening.

1. 1Home | Picteruspicterus.com
2. 2Products | Picteruspicterus.com
3. 3About Us | Picteruspicterus.com
4. 4Picterus AS (Norway) - Wikidatawikidata.org